@article {1653603,
	title = {Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review},
	journal = {Am J Ophthalmol Case Rep},
	volume = {27},
	year = {2022},
	month = {2022 Sep},
	pages = {101634},
	abstract = {Purpose: To investigate the clinical response to infliximab in ocular inflammation patients who develop anti-infliximab antibodies (AIA) vs. those patients who do not develop AIA. Observations: A retrospective review was performed of patients treated with infliximab for noninfectious uveitis (NIU) or scleritis. Clinical response was determined as a composite clinical endpoint and classified as complete, partial, or absent. Nine of 32 infliximab-treated patients (28\%) were found to develop AIA. Among the AIA-positive patients, clinical response was complete in 7 patients (78\%) and partial in 2 patients (22\%). Among the AIA-negative patients, clinical response was complete in 15 patients (65\%), partial in 6 patients (26\%) and absent in 2 patients (9\%). Serum infliximab levels tended to decrease with appearance of AIA but rarely became undetectable. Conclusions and Importance: In this pilot study, AIA-positive patients did not have diminished clinical response to infliximab when compared with AIA-negative patients. There was a high rate of complete clinical response to infliximab in this group of NIU and scleritis patients. Approximately a quarter of patients developed AIA. AIA-positive patients did not have diminished rates of clinical response when compared with AIA-negative patients. This suggests that routine AIA monitoring may not be clinically useful, although validation of this finding in larger cohorts is necessary.},
	issn = {2451-9936},
	doi = {10.1016/j.ajoc.2022.101634},
	author = {Valdes, Lianna and Cox, Jacob T and Yang, Janine and Susarla, Gayatri and Han, Samuel and Papaliodis, George N and Sobrin, Lucia}
}
